11/21/2016 1 Miami Neuro Symposium 2016 THE B.E.S.T. TREATMENT OF ACUTE ISCHEMIC STROKE Dr. Felipe de los Rios Medical Director Stroke Program – Baptist Health South Florida Comprehensive Stroke Center - Baptist Hospital of Miami Conflict of Interests None. Objectives Understand the therapies available for the treatment of acute ischemic stroke Identify which patients are eligible for intravenous IV tPA and/or endovascular reperfusion therapies Implement best practices in the treatment of acute ischemic stroke
14
Embed
THE B.E.S.T. TREATMENT OF ACUTE ISCHEMIC STROKE...Implement best practices in the treatment of acute ischemic stroke . 11/21/2016 2 Outline Epidemiology IV thrombolysis ... Riedel
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
11/21/2016
1
Miami Neuro Symposium 2016
THE B.E.S.T. TREATMENT OF
ACUTE ISCHEMIC STROKE
Dr. Felipe de los Rios
Medical DirectorStroke Program – Baptist Health South FloridaComprehensive Stroke Center - Baptist Hospital of Miami
Conflict of Interests
� None.
Objectives
� Understand the therapies available for the treatment of acute ischemic stroke
� Identify which patients are eligible for intravenous IV tPA and/or endovascular reperfusion therapies
� Implement best practices in the treatment of acute ischemic stroke
11/21/2016
2
Outline
� Epidemiology
� IV thrombolysis
� Which patients benefit
� Who is at increased risk of complications
� How to manage post rtPA hemorrhagic conversion
� Endovascular treatment
� Which patients benefit
� Overview of treatment impact
� BEST practices
Stroke
� Prevalence is estimated at 6.6 million Americans ≥ 20 years old
� Incidence is estimated at 795,000 people every year
� 1 in 6 men will have a stroke during their lifetime
� 1 in 5 women will have a stroke during their lifetime
� Worldwide it is the 2nd cause of death and disability
� 67% of all ischemic strokes occur in LMIC´s
Mozaffarian D, Circulation 2015.
87%
10%3%
87% of all stroke is ischemic
Ischemic
Hemorragic
Sub-arachnoid
GCNKSS, NINDS, 1999
11/21/2016
3
IV Thrombolysis
Hypothetical representation of 16 patients treated with t-PA vs 16 patients treated with placebo based on NINDS results at 3 months.
Placebo
T-PA
11/21/2016
4
Low recanalization rates with proximal occlusions
Tomsick et al (2010) Neurology
Logistic regression curve representing an estimate of the probability for successful recanalization of occluded vessels by intravenous thrombolysis (IVT) depending on thrombus
length.
Riedel C H et al. Stroke. 2011;42:1775-1777
Figure 1. Sonographic pattern of clot lysis during tPA infusion among stroke subtypes.
Molina CA, Stroke 2004.
11/21/2016
5
Increase the risk of hemorrhagic conversion
� Size of ischemia
� Advanced patient age
� Prior use of anticoagulants or aspirin
� History of heart failure
� Elevated BP
� Presence of microbleeds by MRI (GRE sequence).
� Endocarditis (symptomatic transformation risk 20% vs 6.5%)
Time is brain
Hacke, Lancet, 2004
11/21/2016
6
Required tests
� Non contrasted head ct scan
� Serum glucose
� Oxygen saturation
� CBC, including platelet count
� Creatinine, BUN
� Electrolytes
� Coagulation profile: PT, PTT, INR
� ECG
� Markers of cardiac ischemia
Guidelines for the Early Management of Patients With Acute Ischemic Stroke. AHA / ASA Stroke. 2013
HCT scan and glucose is enough if:
� No use of anticoagulants
� No active cancer
� No renal or liver disease
� No alcohol or drug abuse
� No suspicion for coagulopathy or thrombocytopenia
Guidelines for the Early Management of Patients With Acute Ischemic Stroke. AHA / ASA Stroke. 2013
Who qualifies?
� Inclusion criteria
� Diagnosis of ischemic stroke causing measurable neurological deficit
� Onset of symptoms <4.5 h before treatment initiation
� Age ≥18 years old
Guidelines for the Early Management of Patients With Acute Ischemic Stroke. AHA / ASA Stroke. 2013
11/21/2016
7
Minor stroke & rapidly improving
� Discharge outcomes
� 27% not discharged home
� 27.2% did not ambulate independently
� Significant component of cognitive dysfunction, fatigue, depression.
� Higher risk of deterioration:
� Higher initial stroke severity and visible arterial occlusion
� Risk of hemorrhagic transformation is lower (0-2%)
Romano JG, et al. Stroke, 2016.
Guidelines for the Early Management of Patients With Acute Ischemic Stroke. AHA / ASA Stroke. 2013
Rapidly improving Stroke Symptoms as an exclusion criteria
� Improvement to a mild stroke such that any remaining deficits seem non-disabling
� Any of the following typically should be considered disabling deficits:
� Complete hemianopsia (≥2 on NIHSS question 3)
� severe aphasia (≥2 on NIHSS question 9)
� Visual or sensory extinction (≥1 on NIHSS question 11)
� Any weakness limiting sustained effort against gravity (≥2 on NIHSS question 6 or 7)
� Any deficits that lead to a total NIHSS score >5
� Any remaining deficit considered potentially disabling in the view of the patient and the treating practitioner. Clinical judgment is required.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke. AHA / ASA. Stroke 2016
� Acute ischemic stroke receiving intravenous r-tPA within 4.5 hours of onset according to guidelines from professional medical societies
� Causative occlusion of the ICA or proximal MCA (M1)
� Age ≥18 years
� NIHSS score of ≥6
� ASPECTS of ≥6, and
� Treatment can be initiated (groin puncture) within 6 hours of symptom onset
Powers WJ. 2015 AHA / ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment. Stroke, 2015.
11/21/2016
10
Modified Ranking Scale (MRS)
ASPECTS Score
www.aspectsinstroke.com
Positive trials
� MR CLEAN (2015)
� ESCAPE (2015)
� SWIFT PRIME (2015)
� EXTEND – IA (2015)
� REVASCAT (2015)
11/21/2016
11
Benefit up to 7.3 hours?
Saver JL. Time to Treatment With Endovascular Thrombectomyand Outcomes From Ischemic Stroke: A Meta-analysis. JAMA
2016
MR CLEAN
� Design: Open label, multicenter, RCT with blinded end-point evaluation between 2010 and 2014.